ArticleAntimicrobial agents and chemotherapy2018
Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Clostridioides difficile : A suspected pro-carcinogenic bacterium for gastrointestinal tumors.Chinese medical journal · 2026Review
- Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition.Gastroenterology · 2025Article
- Synthetic niclosamide-loaded controlled-release nanospheres with high solubility and stability exerting multiple effects againstFrontiers in microbiology · 2025Article
- Exploring the Toxin-Mediated Mechanisms inMicroorganisms · 2024Review
- A leaky human colon model reveals uncoupled apical/basal cytotoxicity in earlyAmerican journal of physiology. Gastrointestinal and liver physiology · 2023Article
- Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Effect of Doxycycline in Decreasing the Severity ofAntibiotics (Basel, Switzerland) · 2022Article
- Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis.Gut pathogens · 2022Article
- ADS024, aFrontiers in microbiology · 2022Article
- Article
- A novel macrolide derivative ameliorates smoke-induced inflammation and emphysema by inhibiting NF-κB activation.American journal of translational research · 2021Article
- Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice.The Journal of infectious diseases · 2020Article
- Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.Gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Hon Wai KoonCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Jiani WangCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Caroline C MussattoCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Christina OrtizCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Elaine C LeeCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Diana Hoang-Ngoc TranCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
Xinhua ChenDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Ciaran P KellyDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Charalabos PothoulakisCenter for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA cpothoulakis@mednet.ucla.edu.
University of California, Los Angeles · USBeth Israel Deaconess Medical Center · USFirst Hospital of China Medical University · CNHarvard University · US
Funding
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0MDecoding Antibiotic-induced Susceptibility to Clostridium difficile InfectionU01AI124290 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BRITTON, ROBERT A, GAREY, KEVIN W · 2016 to 2020
$7.9MCombination Clostridium Difficile Toxin and Adhesin VaccineR01AI095256 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI HO, DAVID D, KELLY, CIARAN P · 2012 to 2015
$1.3MRole of Cathelicidin in Intestinal InflammationK01DK084256 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOON, HON WAI · 2010 to 2014
$743kCombination Clostridium Difficile Toxin and Adhesin VaccineR56AI095256 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI HO, DAVID D, KELLY, CIARAN P · 2011 to 2011
$742kRole of Cathelicidin in Obesity and DiabetesR03DK103964 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOON, HON WAI · 2015 to 2016
$154kNIAID NIH HHS R01 AI095256NIAID NIH HHS R56 AI095256NIAID NIH HHS U01 AI124290NIDDK NIH HHS K01 DK084256NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R03 DK103964
Abstract
PubMed holds no abstract for this paper.
Indexed as
AminoglycosidesAnimalsApoptosisBacterial ProteinsBacterial ToxinsCell LineClostridioides difficileEnterotoxinsEpithelial CellsFidaxomicinHumansInflammationInterleukin-1betaIntestinal MucosaMiceNF-kappa BAminoglycosidesBacterial ProteinsBacterial ToxinsEnterotoxinsFidaxomicinIL1B protein, humanInterleukin-1betaNF-kappa BOP-1118tcdA protein, Clostridium difficileTetradecanoylphorbol AcetatetoxB protein, Clostridium difficileTumor Necrosis Factor-alphaantibioticsClostridium difficile infectionsignaling
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.